Loading…
Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation
Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome or acute leukemia, with very few malignant lympho...
Saved in:
| Published in: | International journal of hematology 2023-02, Vol.117 (2), p.287-292 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3 |
| container_end_page | 292 |
| container_issue | 2 |
| container_start_page | 287 |
| container_title | International journal of hematology |
| container_volume | 117 |
| creator | Taniguchi, Shiho Utsumi, Sae Kochi, Yu Taya, Yuki Mori, Yasuo Semba, Yu-ichiro Sugio, Takeshi Miyawaki, Kohta Kikushige, Yoshikane Kunisaki, Yuya Yoshimoto, Goichi Numata, Akihiko Kato, Koji Uchida, Naoyuki Maeda, Takahiro Miyamoto, Toshihiro Taniguchi, Shuichi Akashi, Koichi |
| description | Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome or acute leukemia, with very few malignant lymphoma reported. We herein present another case of donor-derived Burkitt lymphoma that occurred 9 years after allo-HSCT under continued administration of immunosuppressants for chronic graft-versus-host disease (GVHD). The patient achieved a partial response after rituximab-combined intensive chemotherapy. To reduce the risk of relapse and to avoid organ toxicities due to repeated chemotherapies, we performed upfront high-dose chemotherapy followed by stem cell rescue using donor-derived CD34
+
cells, called pseudo-autologous HSCT (pASCT), and adjusted immunosuppressants appropriately. The patient remained disease-free for 23 months after pASCT without exacerbation of cGVHD. Although the observation period has been relatively short and longer follow-up is needed, pASCT may be a feasible option for donor-derived lymphoma even in patients with active cGVHD. |
| doi_str_mv | 10.1007/s12185-022-03458-x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2890339878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890339878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3</originalsourceid><addsrcrecordid>eNp9kUtP3DAUha2qqDNA_0AXyFLXBj-S2F62I14SUhfA2vI419PQJA5-IOY_8KPJdCiVuujq3sU535HOQegLo6eMUnmWGGeqJpRzQkVVK_L8AS2ZamoipKw-oiXVvCa1ZHSBDlN6oJRJWslPaCEaJhrO5RK93BbnICVfejwlKG0gtuTQh00oCacMA3bQ9zhHO6apt2O2uQsj9iHiNowhkhZi9wQt_l7iry5n3G-H6WcYLA7OlRi7cYM13oKNCVufIWLbz3QYoXP_Uo_Rgbd9gs9v9wjdX5zfra7IzY_L69W3G-KE1pl4KRqQTVM5751kXDDttarXSq4lMMHb-We1UsyD0Nyua0ErrXhrgVMOjRdH6OueO8XwWCBl8xBKHOdIw5WmQmgl1azie5WLIaUI3kyxG2zcGkbNbgCzH8DMA5jfA5jn2XTyhi7rAdp3y5_GZ4HYC9K06wbi3-z_YF8B9raVPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890339878</pqid></control><display><type>article</type><title>Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation</title><source>Springer Link</source><creator>Taniguchi, Shiho ; Utsumi, Sae ; Kochi, Yu ; Taya, Yuki ; Mori, Yasuo ; Semba, Yu-ichiro ; Sugio, Takeshi ; Miyawaki, Kohta ; Kikushige, Yoshikane ; Kunisaki, Yuya ; Yoshimoto, Goichi ; Numata, Akihiko ; Kato, Koji ; Uchida, Naoyuki ; Maeda, Takahiro ; Miyamoto, Toshihiro ; Taniguchi, Shuichi ; Akashi, Koichi</creator><creatorcontrib>Taniguchi, Shiho ; Utsumi, Sae ; Kochi, Yu ; Taya, Yuki ; Mori, Yasuo ; Semba, Yu-ichiro ; Sugio, Takeshi ; Miyawaki, Kohta ; Kikushige, Yoshikane ; Kunisaki, Yuya ; Yoshimoto, Goichi ; Numata, Akihiko ; Kato, Koji ; Uchida, Naoyuki ; Maeda, Takahiro ; Miyamoto, Toshihiro ; Taniguchi, Shuichi ; Akashi, Koichi</creatorcontrib><description>Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome or acute leukemia, with very few malignant lymphoma reported. We herein present another case of donor-derived Burkitt lymphoma that occurred 9 years after allo-HSCT under continued administration of immunosuppressants for chronic graft-versus-host disease (GVHD). The patient achieved a partial response after rituximab-combined intensive chemotherapy. To reduce the risk of relapse and to avoid organ toxicities due to repeated chemotherapies, we performed upfront high-dose chemotherapy followed by stem cell rescue using donor-derived CD34
+
cells, called pseudo-autologous HSCT (pASCT), and adjusted immunosuppressants appropriately. The patient remained disease-free for 23 months after pASCT without exacerbation of cGVHD. Although the observation period has been relatively short and longer follow-up is needed, pASCT may be a feasible option for donor-derived lymphoma even in patients with active cGVHD.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-022-03458-x</identifier><identifier>PMID: 36136227</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Allografts ; Autografts ; Burkitt Lymphoma - etiology ; Burkitt Lymphoma - therapy ; Burkitt's lymphoma ; Case Report ; CD34 antigen ; Chemotherapy ; Complications ; Graft vs Host Disease - diagnosis ; Graft vs Host Disease - etiology ; Graft vs Host Disease - pathology ; Graft-versus-host reaction ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; Humans ; Immunosuppressive Agents ; Leukemia ; Leukemia, Myeloid, Acute - complications ; Lymphoma ; Lymphoma - complications ; Malignancy ; Medicine ; Medicine & Public Health ; Myelodysplastic syndrome ; Oncology ; Rituximab ; Stem cell transplantation ; Stem cells ; Transplantation ; Transplantation, Autologous ; Transplantation, Homologous - adverse effects</subject><ispartof>International journal of hematology, 2023-02, Vol.117 (2), p.287-292</ispartof><rights>Japanese Society of Hematology 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. Japanese Society of Hematology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3</citedby><cites>FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3</cites><orcidid>0000-0001-6425-1720</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36136227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taniguchi, Shiho</creatorcontrib><creatorcontrib>Utsumi, Sae</creatorcontrib><creatorcontrib>Kochi, Yu</creatorcontrib><creatorcontrib>Taya, Yuki</creatorcontrib><creatorcontrib>Mori, Yasuo</creatorcontrib><creatorcontrib>Semba, Yu-ichiro</creatorcontrib><creatorcontrib>Sugio, Takeshi</creatorcontrib><creatorcontrib>Miyawaki, Kohta</creatorcontrib><creatorcontrib>Kikushige, Yoshikane</creatorcontrib><creatorcontrib>Kunisaki, Yuya</creatorcontrib><creatorcontrib>Yoshimoto, Goichi</creatorcontrib><creatorcontrib>Numata, Akihiko</creatorcontrib><creatorcontrib>Kato, Koji</creatorcontrib><creatorcontrib>Uchida, Naoyuki</creatorcontrib><creatorcontrib>Maeda, Takahiro</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Taniguchi, Shuichi</creatorcontrib><creatorcontrib>Akashi, Koichi</creatorcontrib><title>Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome or acute leukemia, with very few malignant lymphoma reported. We herein present another case of donor-derived Burkitt lymphoma that occurred 9 years after allo-HSCT under continued administration of immunosuppressants for chronic graft-versus-host disease (GVHD). The patient achieved a partial response after rituximab-combined intensive chemotherapy. To reduce the risk of relapse and to avoid organ toxicities due to repeated chemotherapies, we performed upfront high-dose chemotherapy followed by stem cell rescue using donor-derived CD34
+
cells, called pseudo-autologous HSCT (pASCT), and adjusted immunosuppressants appropriately. The patient remained disease-free for 23 months after pASCT without exacerbation of cGVHD. Although the observation period has been relatively short and longer follow-up is needed, pASCT may be a feasible option for donor-derived lymphoma even in patients with active cGVHD.</description><subject>Allografts</subject><subject>Autografts</subject><subject>Burkitt Lymphoma - etiology</subject><subject>Burkitt Lymphoma - therapy</subject><subject>Burkitt's lymphoma</subject><subject>Case Report</subject><subject>CD34 antigen</subject><subject>Chemotherapy</subject><subject>Complications</subject><subject>Graft vs Host Disease - diagnosis</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - pathology</subject><subject>Graft-versus-host reaction</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Immunosuppressive Agents</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - complications</subject><subject>Lymphoma</subject><subject>Lymphoma - complications</subject><subject>Malignancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Myelodysplastic syndrome</subject><subject>Oncology</subject><subject>Rituximab</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Transplantation, Homologous - adverse effects</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kUtP3DAUha2qqDNA_0AXyFLXBj-S2F62I14SUhfA2vI419PQJA5-IOY_8KPJdCiVuujq3sU535HOQegLo6eMUnmWGGeqJpRzQkVVK_L8AS2ZamoipKw-oiXVvCa1ZHSBDlN6oJRJWslPaCEaJhrO5RK93BbnICVfejwlKG0gtuTQh00oCacMA3bQ9zhHO6apt2O2uQsj9iHiNowhkhZi9wQt_l7iry5n3G-H6WcYLA7OlRi7cYM13oKNCVufIWLbz3QYoXP_Uo_Rgbd9gs9v9wjdX5zfra7IzY_L69W3G-KE1pl4KRqQTVM5751kXDDttarXSq4lMMHb-We1UsyD0Nyua0ErrXhrgVMOjRdH6OueO8XwWCBl8xBKHOdIw5WmQmgl1azie5WLIaUI3kyxG2zcGkbNbgCzH8DMA5jfA5jn2XTyhi7rAdp3y5_GZ4HYC9K06wbi3-z_YF8B9raVPA</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Taniguchi, Shiho</creator><creator>Utsumi, Sae</creator><creator>Kochi, Yu</creator><creator>Taya, Yuki</creator><creator>Mori, Yasuo</creator><creator>Semba, Yu-ichiro</creator><creator>Sugio, Takeshi</creator><creator>Miyawaki, Kohta</creator><creator>Kikushige, Yoshikane</creator><creator>Kunisaki, Yuya</creator><creator>Yoshimoto, Goichi</creator><creator>Numata, Akihiko</creator><creator>Kato, Koji</creator><creator>Uchida, Naoyuki</creator><creator>Maeda, Takahiro</creator><creator>Miyamoto, Toshihiro</creator><creator>Taniguchi, Shuichi</creator><creator>Akashi, Koichi</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0000-0001-6425-1720</orcidid></search><sort><creationdate>20230201</creationdate><title>Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation</title><author>Taniguchi, Shiho ; Utsumi, Sae ; Kochi, Yu ; Taya, Yuki ; Mori, Yasuo ; Semba, Yu-ichiro ; Sugio, Takeshi ; Miyawaki, Kohta ; Kikushige, Yoshikane ; Kunisaki, Yuya ; Yoshimoto, Goichi ; Numata, Akihiko ; Kato, Koji ; Uchida, Naoyuki ; Maeda, Takahiro ; Miyamoto, Toshihiro ; Taniguchi, Shuichi ; Akashi, Koichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allografts</topic><topic>Autografts</topic><topic>Burkitt Lymphoma - etiology</topic><topic>Burkitt Lymphoma - therapy</topic><topic>Burkitt's lymphoma</topic><topic>Case Report</topic><topic>CD34 antigen</topic><topic>Chemotherapy</topic><topic>Complications</topic><topic>Graft vs Host Disease - diagnosis</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - pathology</topic><topic>Graft-versus-host reaction</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Immunosuppressive Agents</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - complications</topic><topic>Lymphoma</topic><topic>Lymphoma - complications</topic><topic>Malignancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Myelodysplastic syndrome</topic><topic>Oncology</topic><topic>Rituximab</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Transplantation, Homologous - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taniguchi, Shiho</creatorcontrib><creatorcontrib>Utsumi, Sae</creatorcontrib><creatorcontrib>Kochi, Yu</creatorcontrib><creatorcontrib>Taya, Yuki</creatorcontrib><creatorcontrib>Mori, Yasuo</creatorcontrib><creatorcontrib>Semba, Yu-ichiro</creatorcontrib><creatorcontrib>Sugio, Takeshi</creatorcontrib><creatorcontrib>Miyawaki, Kohta</creatorcontrib><creatorcontrib>Kikushige, Yoshikane</creatorcontrib><creatorcontrib>Kunisaki, Yuya</creatorcontrib><creatorcontrib>Yoshimoto, Goichi</creatorcontrib><creatorcontrib>Numata, Akihiko</creatorcontrib><creatorcontrib>Kato, Koji</creatorcontrib><creatorcontrib>Uchida, Naoyuki</creatorcontrib><creatorcontrib>Maeda, Takahiro</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Taniguchi, Shuichi</creatorcontrib><creatorcontrib>Akashi, Koichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taniguchi, Shiho</au><au>Utsumi, Sae</au><au>Kochi, Yu</au><au>Taya, Yuki</au><au>Mori, Yasuo</au><au>Semba, Yu-ichiro</au><au>Sugio, Takeshi</au><au>Miyawaki, Kohta</au><au>Kikushige, Yoshikane</au><au>Kunisaki, Yuya</au><au>Yoshimoto, Goichi</au><au>Numata, Akihiko</au><au>Kato, Koji</au><au>Uchida, Naoyuki</au><au>Maeda, Takahiro</au><au>Miyamoto, Toshihiro</au><au>Taniguchi, Shuichi</au><au>Akashi, Koichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>117</volume><issue>2</issue><spage>287</spage><epage>292</epage><pages>287-292</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome or acute leukemia, with very few malignant lymphoma reported. We herein present another case of donor-derived Burkitt lymphoma that occurred 9 years after allo-HSCT under continued administration of immunosuppressants for chronic graft-versus-host disease (GVHD). The patient achieved a partial response after rituximab-combined intensive chemotherapy. To reduce the risk of relapse and to avoid organ toxicities due to repeated chemotherapies, we performed upfront high-dose chemotherapy followed by stem cell rescue using donor-derived CD34
+
cells, called pseudo-autologous HSCT (pASCT), and adjusted immunosuppressants appropriately. The patient remained disease-free for 23 months after pASCT without exacerbation of cGVHD. Although the observation period has been relatively short and longer follow-up is needed, pASCT may be a feasible option for donor-derived lymphoma even in patients with active cGVHD.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>36136227</pmid><doi>10.1007/s12185-022-03458-x</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6425-1720</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2023-02, Vol.117 (2), p.287-292 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_journals_2890339878 |
| source | Springer Link |
| subjects | Allografts Autografts Burkitt Lymphoma - etiology Burkitt Lymphoma - therapy Burkitt's lymphoma Case Report CD34 antigen Chemotherapy Complications Graft vs Host Disease - diagnosis Graft vs Host Disease - etiology Graft vs Host Disease - pathology Graft-versus-host reaction Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Humans Immunosuppressive Agents Leukemia Leukemia, Myeloid, Acute - complications Lymphoma Lymphoma - complications Malignancy Medicine Medicine & Public Health Myelodysplastic syndrome Oncology Rituximab Stem cell transplantation Stem cells Transplantation Transplantation, Autologous Transplantation, Homologous - adverse effects |
| title | Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T03%3A53%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20pseudo-autologous%20stem%20cell%20transplantation%20for%20donor-derived%20Burkitt%20lymphoma%20occurring%209%20years%20after%20allogeneic%20transplantation&rft.jtitle=International%20journal%20of%20hematology&rft.au=Taniguchi,%20Shiho&rft.date=2023-02-01&rft.volume=117&rft.issue=2&rft.spage=287&rft.epage=292&rft.pages=287-292&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-022-03458-x&rft_dat=%3Cproquest_cross%3E2890339878%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c399t-f736e7664cffc712319f985b87b7e132d85b15881fe392ab5304982dae202e6f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2890339878&rft_id=info:pmid/36136227&rfr_iscdi=true |